News & Updates

Simultaneous COVID-19 and influenza testing can protect high-risk groups

COVID-19 and influenza continue to pose severe public health challenge post-pandemic.

Rapid diagnostic tests that can differentiate between COVID-19 and influenza are essential for accurate diagnosis, care, and treatment.^1,2

Evidence supports semaglutide for obesity-related HFpEF

Semaglutide improves exercise function in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) in a secondary analysis of the prespecified pooled STEP-HFpEF and STEP-HFpEF DM trials presented at HFSA 2024.

Patients with acute anterior uveitis prone to ipsilateral recurrence

Recurrence in the ipsilateral eye is not uncommon in nearly half of patients with acute anterior uveitis (AAU), while one in four may experience recurrence in the contralateral eye, suggests a study.

Vasopressin injection reduces bleeding, surgery time in ovarian endometrioma cystectomy

In women with ovarian endometrioma, those who receive vasopressin injection during laparoscopic cystectomy experience shorter operation time, have reduced blood loss, and fewer coagulation events, as shown in a study presented at RCOG 2024.

Faricimab trumps aflibercept in diabetic macular edema

Treatment with faricimab demonstrates similar visual acuity and greater retinal thickness reduction, with fewer injections, when compared with aflibercept therapy in patients with diabetic macular edema (DME), reports a recent study.

Early smoking cessation boosts cancer survival

Quitting smoking within 6 months after receiving a cancer diagnosis appears to confer survival benefits, according to a study.

Over 39M people could die from superbugs by 2050

More than 39 million people worldwide could die from antibiotic-resistant infections from 2025 to 2050 as the superbug crisis intensifies, according to a new global analysis of antimicrobial resistance.

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

Including adjuvant nivolumab as part of a perioperative regimen for resectable NSCLC further improves the EFS benefit vs including nivolumab in a neoadjuvant-only setting, as suggested by a patient-level data analysis of CheckMate 77T and CheckMate 816 investigating each modality separately